거래 정지 중인 종목 2026-06-04 이후 거래가 정지되었습니다. 재개될 수 있으며, 표시된 시세는 마지막 거래일 기준입니다.
DVAX
Dynavax Technologies Corp
$15.50
+0.00 +0.00%
다이나백스 테크놀로지스(DVAX) is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
시가총액
$1.8B
스몰캡
P/E
-
배당수익률
없음
52주 위치
96%
저점 +68% · 고점 -1%
애널리스트
적극 매수
B+
Fundamental health
vs. 전체 시장
수익성 Top 30%
성장 Top 38%
밸류에이션 Top 24%
재무 안정 Top 24%
| Index | - | P/E | - | EPS (ttm) | -0.38 | Insider Own | 0.18% | Shs Outstand | 117.4M | Perf Week | - |
| Market Cap | 1.82B | Forward P/E | - | EPS next Y | - | Insider Trans | -91.25% | Shs Float | 116.5M | Perf Month | -1.15% |
| Enterprise Value | 1.46B | PEG | - | EPS next Q | - | Inst Own | 95.93% | Short Float | 8.4% | Perf Quarter | 39.14% |
| Income | -0.04B | P/S | 5.51 | EPS this Y | - | Inst Trans | - | Short Ratio | 3.12 | Perf Half Y | 47.76% |
| Sales | 0.33B | P/B | 3.41 | EPS next 5Y | - | ROA | -4.32% | Short Interest | 9.79M | Perf YTD | 0.78% |
| Book/sh | 4.55 | P/C | 2.81 | EPS past 3/5Y | -27.72% - | ROE | -7.14% | 52W High | -1.46% ($15.73) | Perf Year | 17.87% |
| Cash/sh | 5.52 | P/FCF | 22.6 | Sales past 3/5Y | -14.08% 51.08% | ROIC | -5.57% | 52W Low | 68.48% ($9.20) | Perf 3Y | 40.91% |
| Dividend Est. | - | EV/EBITDA | 78.23 | EPS Y/Y TTM | -310.39% | Gross Margin | 83.17% | Volatility(W/M) | 0.23% 0.4% | Perf 5Y | 46.23% |
| Dividend TTM | - | EV/Sales | 4.42 | Sales Y/Y TTM | 26.73% | Oper. Margin | 3.16% | ATR (14) | 0.11 | Perf 10Y | -14.88% |
| Dividend Ex-Date | - | Quick Ratio | 6.94 | EPS Q/Q | 81.6% | Profit Margin | -13.13% | RSI (14) | 76 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 7.62 | Sales Q/Q | 17.67% | SMA20 | -0.38% ($15.56) | Beta | 0.93 | Target Price | $16 |
| Payout | - | Debt/Eq | 0.54 | Earnings | 2025/11/5 | SMA50 | 12.55% ($13.77) | Rel Volume | 0 | Prev Close | $15.5 |
| Employees | 405 | LT Debt/Eq | 0.46 | EPS/Sales Surpr. | 66.53% 0.93% | SMA200 | 38.23% ($11.21) | Avg Volume(3M) | 3.14M | Price | $15.5 |
| IPO | 2004/2/19 | Option/Short | Yes/No | Trades | 0 | Volume | - | Change | - |
Quarterly earnings trend Quarterly earnings data is not yet available — foreign-listed companies (ADRs) only file annual reports with the U.S., and recently listed companies may not have filed their first quarterly report.
Dynavax Technologies Corp (DVAX) Investment Analysis
What kind of company is Dynavax Technologies Corp?
다이나백스 테크놀로지스(DVAX)
Healthcare · Drug Manufacturers - Specialty & Generic
Healthcare Stocks
💉 A biotech company specializing in vaccines. HEPLISAV-B, a hepatitis B vaccine, is experiencing high growth. 2025 revenue is projected between $15M and $325M, with a market share of 45%. Acquired by Sanofi (Q1 2026).
Learn more about Dynavax Technologies Corp →Market Cap
$1.8B
Approx. KRW 2.5 trillion
⚖️ 1% of Samsung Electronics
Market Cap Rank2113
Employees405people
IPO2004/02/19
Current Price$15.50 ≈ 21,235원
Key Events
예정된 이벤트가 없습니다
DVAX의 다음 실적 발표일이나 배당 일정이 아직 수집되지 않았습니다.
- 실적 발표는 보통 분기마다 있습니다
- 배당주는 연 1~4회 배당락일이 있습니다
Is it profitable?
Financially sound but profitability is low
Losses or thin margins — early-stage growth or weakening competitiveness
Profitability — How efficiently it makes money
Operating Margin
Profit kept from selling products and services (higher is better)
3.2%
✓ 평균
Net Margin
Share of revenue left after taxes and interest are paid
-13.1%
✓ 적자
Gross Margin
Profit after subtracting raw-material costs only (signals product competitiveness)
83.2%
✓ 우수
ROE
Annual return earned on shareholders' equity (15%+ is strong)
-7.1%
✓ 적자
ROA
Annual earnings relative to total company assets
-4.3%
✓ 적자
ROIC
Return generated per dollar invested in the business
-5.6%
✓ 적자
Financial health — Debt & liquidity burden
Debt-to-Equity (D/E)
Debt relative to equity (lower is healthier)
0.54
✓ Average
Current Ratio
Liquid assets available to cover liabilities due within a year
7.62
✓ 우수
Quick Ratio
Liquid assets excluding inventory, available for immediate use
6.94
✓ 우수
* Ratings reflect relative position vs. peer-group distribution (same sector & size) plus absolute guards (loss & risk thresholds).
What's the outlook?
Mixed Outlook
Positive and negative signals are mixed
애널리스트 목표가
$16.00
현재가 대비 +3.2%
💡 12개월 이내 도달을 전망하는 애널리스트 컨센서스 평균
⚠ 이 데이터는 애널리스트 추정치이며 실제 결과와 다를 수 있습니다. 투자 결정은 추가 검토와 함께 하세요.
Did earnings meet expectations?
Insufficient historical earnings data
No analyzable past earnings releases have been collected yet.
Is it growing?
Average Growth
Mid-range within the industry
Declining Growth EPS or revenue is declining — check for structural issues or economic sensitivity
📊 How much has it grown? (actual results)
Past 3-Year EPS
Actual average annual EPS growth over the past 3 years
-27.7%
부진
Past 5-Year Revenue
How much revenue grew over the past 5 years
+51.1%
우수
⚡ Short-term momentum
QoQ Revenue
Revenue change from the previous quarter (short-term momentum)
+17.7%
양호
* Forecast values are analyst consensus estimates. Ratings are determined by relative position vs. peer group of the same growth style and size.
New to investing terms? Look it up in the financial dictionary →
Has the stock risen over the long term?
Underperformed the market by 22%p over 5 years
DVAX +46.2% · S&P 500 +68.3%
Excess return vs. market (price-based, ex-dividends)
5-year basis
vs S&P 500
-22.1%p
behind the market
vs Health Care (XLV)
+21.7%p
ahead of the sector average
1-year basis
vs S&P 500
+1.9%p
roughly in line with the market
vs Health Care (XLV)
-1.8%p
roughly in line with the sector average
Current position within 52-week range
Low (-68.5%p) High (-1.5%p)
Current price is 68.5% above the 52-week low and 1.5% below the 52-week high
Recent risk (last 21 trading days)
Max drawdown
-0.3%
Annualized volatility
1.3%
Is it attractive at this price?
In line with the industry average
Pricey on Vs. Cash Flow, In line with peers on Vs. Assets·Vs. Sales
💡 How to read this — Compare against peers in the same industry to see what the price is cheap or expensive relative to. Example: cheap vs. earnings = stock price is low relative to what the company earns; expensive vs. assets = stock price is high relative to assets on the balance sheet.
Vs. Assets Mid-range
Vs. Sales Mid-range
Vs. Cash Flow Pricey
🏢 Vs. Assets
PBR Price-to-Book Ratio
Price vs. the company's asset value — below 1 trades cheaper than assets
3.41x
✓ Fair
🧾 Vs. Sales
PSR Price-to-Sales Ratio
Market cap vs. revenue — lower is cheaper relative to sales
5.51x
✓ Fair
💧 Vs. Cash Flow
EV/EBITDA Enterprise Value Multiple
Total enterprise value ÷ operating cash earnings — a benchmark for M&A
78.23x
✓ Very pricey
💧 Vs. Cash Flow
P/FCF Price-to-Free-Cash-Flow Ratio
Price vs. actual cash generation — lower means more efficient
22.60x
✓ Fair
Analyst target price (reference)
$16.00 vs. current price +3.2%
* Valuation is the stock's relative position within the industry peer group (same sector and market-cap range). Even when valuation looks attractive, check the 'Profitability' and 'Growth' sections too.
As of: Recent snapshot · Peer group: 전체 시장
Who owns it?
Ownership flow shows some pressure
Insider net selling -91.3% · Short interest moderate 8.4% · Short interest fell -0.7%p over the last 21 days
📈 Recent trading flow (6 months)
🧑💼 Insiders (executives & directors)
-91.3%
Insiders large net selling
🏦 Institutions (funds & investors)
-
No trading data for Institutions
💡 Net change over the past 6 months. Shows how much insiders and institutions increased or reduced their holdings, in %.
👥 Holdings composition
🏦 Institutions 95.9%
Institution-led, stable structure
🧑💼 Insiders 0.2%
Low, common among large-caps
👤 Retail investors (estimated) 3.9%
Everyone excluding institutions and insiders
Institutions Insiders Retail (est.)
📉 Short-selling metrics
Short ratio
8.4%
Moderate
Past 21 days 📉 -0.7%p decrease
Short interest days to cover
3.1 days
Days needed to close short positions using average trading volume
🧮 Share count
Total shares outstanding 117.4M주
Float (tradable shares) 116.5M주
* Insider/institutional flows are based on net changes over the past 6 months. Trend is cumulative over the past 21 days.
ETFs holding DVAX
ETFs with the highest weightings · 1 total shown
* Based on official quarterly filings. Latest disclosure; actual current weights may differ.
How much does it pay in dividends?
This company does not pay a dividend
It may be a growth-focused firm reinvesting profits into expansion. Consider this growth-stock profile when investing.
Compare Industry Peers
💡 vs. sector average ▲ Favorable / ▼ Unfavorable (Lower PER and PBR are better; higher ROE and dividend yield are better)
Sorted by market cap, largest first
| Stock | Market Cap | PER | PBR | ROE | Dividend Yield | Change |
|---|---|---|---|---|---|---|
| DVAX This Stock | $1.8B | - | 3.4 ▼ | -7.14% ▲ | - | +0.0% |
LLY | $1.13T | 43.1 ▼ | 36.2 ▼ | 107.64% ▲ | 0.58% ▼ | +0.1% |
JNJ | $640.9B | 30.8 ▼ | 7.5 ▼ | 25.74% ▲ | 2.02% ▲ | +1.0% |
ABBV | $453.9B | 126.7 ▼ | - | 15221.82% ▲ | 2.67% ▲ | -0.9% |
UNH | $379.3B | 26.9 ▼ | 3.9 ▼ | 12.49% ▲ | 2.16% ▲ | -0.7% |
MRK | $323.0B | 36.8 ▼ | 7.0 ▼ | 18.97% ▲ | 2.5% ▲ | -0.2% |
| Sector Avg | - | 26.1 | 2.7 | -48.83% | 1.23% | - |
FAQ
What kind of company is 다이나백스 테크놀로지스(DVAX)?
다이나백스 테크놀로지스(DVAX) belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is the market cap of DVAX?
The market cap of DVAX is approximately $1.8B, ranking 2,113 within its sector.
What is the 52-week high and low for DVAX?
DVAX has recorded a 52-week high of $15.73 and a low of $9.20.
면책조항: 본 콘텐츠는 참고 자료이며 투자 권유가 아닙니다. 모든 투자의 책임은 투자자 본인에게 있습니다.